Stephen W. Ranere

Partner
Boston
  • 200 Clarendon Street
  • Boston, MA 02116
  • USA
Profile Experience

Stephen Ranere is a partner in the Boston office of Latham & Watkins and a member of the firm's Emerging Companies Practice. He represents both public and private companies, along with venture capital firms involved in the technology and life sciences industries.

Mr. Ranere regularly handles a broad range of legal representation, including general corporate counseling, early stage company formation and strategy, initial through late stage venture capital financings, mergers and acquisitions, public securities offerings, and public company representation.

Mr. Ranere was a member of the Suffolk University Law Review and was awarded the Daniel J. Fern Award for highest grade point average.

Prior to law school, Mr. Ranere held business development positions with Sophos, a provider of network anti-virus solutions, and CipherTrust (later acquired by McAfee), a provider of email and internet security products.

Mr. Ranere frequently lends his time and legal advice to local community organizations, including TiE Boston, a nonprofit association dedicated to fostering entrepreneurship, and More Than Words, a nonprofit social enterprise empowering high-risk young adults to take charge of their lives.

Mr. Ranere’s representative transactions include:

Technology
  • Riversand Technologies on its sale to Syndigo
  • Evolv Technology on its US$1.7 billion SPAC merger with NewHold Investment Corporation
  • PathAI on its US$165 million Series C financing
  • Actifio on its sale to Google and numerous debt and equity financings
  • Charles River Systems on its US$2.6 billion sale to State Street Corporation
  • Amphenol on its US$400 million acquisition of SSI Controls Technologies
  • Veracode on its US$614 million sale to CA Technologies
  • CloudHealth on its sale to VMware, Inc.
  • Care.com in its IPO and numerous acquisitions
  • Zipcar on its IPO and sale to Avis Budget Group 
Life Sciences
  • Rapid Micro Biosystems on its IPO and numerous other private financings
  • Neurogene on its US$115 million equity financing and numerous other private financings
  • Kiniksa Pharmaceuticals on its US$150 million IPO and multiple private financings and strategic transactions
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.